What did @elevatemd actually say?
The creator gave a rundown of HRT delivery methods for people in perimenopause, dismissing oral and transdermal options as only useful for "mild symptom management," then taking a hard swing at pellets before landing on injectables as the clear winner. The core argument: pellets produce unpredictable hormone surges, can't be adjusted once inserted, and have no business existing in 2026. Injectables, by contrast, were called "the most bioavailable form out of any other form of HRT" with "the least amount of side effects." The trocar demo, complete with the note that the same device is used in embalming, was clearly designed to shock. It worked. But shock value and accuracy aren't the same thing, so let's untangle what's actually supported here.
Does the science back this up?
The criticism of pellets has real footing in the literature, but the claims about injectables being definitively superior need more nuance than a 60-second TikTok allows. On pellets, the creator is largely right. A 2019 review by Glaser and Dimitrakakis in Maturitas documented significant variability in pellet hormone delivery, with supraphysiologic testosterone levels reported in some patients, particularly women. The irreversibility problem is real and clinically documented. Once a pellet is inserted, you cannot reduce the dose if side effects emerge, and that's a legitimate patient safety concern. On injectables, the bioavailability claim requires context. Injectable testosterone cypionate or estradiol valerate does bypass first-pass liver metabolism, which is an advantage over oral forms. But calling it "the most bioavailable" across all forms oversimplifies things. Transdermal estradiol also avoids first-pass metabolism and has a strong safety profile per the NICE 2015 menopause guidelines and subsequent research.
What did they get wrong (or right)?
They got the pellet criticism mostly right and deserve credit for it. The irreversibility issue is not discussed enough in patient-facing content. A 2021 case series published in the Journal of the Endocrine Society documented adverse events from testosterone pellets in women, including polycythemia and androgenic side effects that persisted for months post-insertion precisely because removal isn't straightforward. Where the video oversimplifies: dismissing patches, creams, and gels as only good for "mild symptom management" is not well-supported. Transdermal estradiol is a first-line option in most evidence-based guidelines, including those from the Menopause Society (formerly NAMS), and is not reserved for mild cases. The claim that injectables have "the least amount of side effects" is also unverified as a blanket statement. Injectable testosterone in women is an off-label use with limited large-scale trial data. The enthusiasm here runs ahead of the evidence. Also worth flagging: the video never mentions progesterone, which is a significant omission for anyone with a uterus considering estrogen therapy.
What should you actually know?
No single HRT delivery method is universally best. The right choice depends on your symptoms, hormone levels, cardiovascular history, and personal preference. Transdermal estradiol is well-studied and appropriate for many people, not just those with mild symptoms. Injectables can be effective and do offer dose flexibility, but the evidence base for injectable estrogen and testosterone in perimenopausal women is thinner than the video implies. The Menopause Society's 2023 position statement notes that individualized treatment remains the standard, with no one-size-fits-all delivery method. Pellets are genuinely controversial among endocrinologists and gynecologists for the reasons the creator outlines, and many major medical organizations do not endorse them as a preferred option. If you're exploring HRT, ask your provider specifically about dose adjustability, monitoring protocols, and what happens if you have a side effect. Those questions matter regardless of which method you choose.